Preventive Health Optimization

Capital is rotating from wearables to clinical-grade diagnostics and metabolic care

Oura's IPO was targeted at a $16B valuation, with 73% of the offering secondary shares. It was postponed indefinitely on market volatility, and Forerunner had planned to sell its entire position. Meanwhile, private rounds are going to companies that tie measurement to clinical action. Nourish raised a $100M Series C, and Thrive frames it as an 'access' investment around GLP-1 persistence. Tiny Health, Teal Health and Neko Health are also drawing capital. Series C deals total $872M across 4 rounds in 90 days, against $11M across 4 seed deals, so late-stage money dominates.

Neko Health's $499 full-body scan is pitched as running profitable clinics with positive unit economics. It is following a 'Spotify playbook' of five years in Sweden, then the UK, then the US. A competing NYC full-body scan clinic is opening, and the founders frame the bet as moving healthcare from reacting to disease toward measuring earlier. Blood-only services such as Function and Superpower, at roughly $350-$400, are being compared unfavorably against this multimodal scope.

Why it matters · Imaging-plus-blood bundles are becoming the reference product, which pressures blood-only subscriptions on price and differentiation.

Teal Health raised a $22M Series A, with a market thesis that consumers are comfortable with home diagnostics and providers want higher screening adherence. Tiny Health's $33M Series B was led by B Capital. It has about 200,000 longitudinal microbiome samples, four published papers, and a $199 provider rate that undercuts inconclusive procedures costing thousands. Hims & Hers also joined a $30M Series A alongside GV, F-Prime and Amgen Ventures.

Why it matters · Evidence-backed, low-cost at-home tests that clinicians can adopt are the most credible route from consumer curiosity to reimbursable prevention.

Whoop now offers lab testing through Quest Diagnostics, and analysts expect wearable sleep and recovery data from Whoop, Oura and Fitbit to be linked to clinical data. Today AI integrates rings and bracelets for context. Current devices still don't measure REM directly, which leaves room for products like Eight Sleep's temperature-controlled system to differentiate.

Why it matters · Hardware-only players need a clinical or AI services layer to retain users and justify subscriptions.

Mark Wahlberg's Municipal Gym will open a 32,000 sq ft club with blood work and epigenetic testing, pitched as the affordable alternative to expensive longevity clubs. Investors such as Michael Brandt describe the body as the next technology platform, spanning wearables, peptides, GLP-1s and ketones.

Why it matters · Celebrity-led, lower-priced longevity offerings widen the consumer funnel but also commoditize testing.